The estimated Net Worth of Evan/ Fa Jones is at least $13.3 Million dollars as of 12 August 2024. Evan Jones owns over 47,845 units of Veracyte Inc stock worth over $156,845 and over the last 14 years Evan sold VCYT stock worth over $13,181,628.
Evan has made over 53 trades of the Veracyte Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Evan sold 47,845 units of VCYT stock worth $1,540,131 on 12 August 2024.
The largest trade Evan's ever made was buying 874,317 units of Veracyte Inc stock on 19 May 2016 worth over $26,509,291. On average, Evan trades about 25,182 units every 60 days since 2011. As of 12 August 2024 Evan still owns at least 5,173 units of Veracyte Inc stock.
You can see the complete history of Evan Jones stock trades at the bottom of the page.
Evan's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo, and Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
Veracyte Inc executives and other stock owners filed with the SEC include: